SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is highly active following the CME Group's recent, repeated increases in margin requirements for silver futures, sparking intense debate among traders who see it as a desperate measure to control a surging market. This volatility is further fueled by conflicting narratives around impending Chinese silver export restrictions and the growing disconnect between paper and physical prices. The community is sharply divided between those predicting a massive short squeeze driven by industrial demand and global supply shifts, and those anticipating a significant pullback.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UP Fintech (NASDAQ:TIGR) Trading 5.4% Higher - Still a Buy?

UP Fintech (NASDAQ:TIGR) Shares Up 5.4% - What's Next...

UP Fintech Holding Limited (NASDAQ:TIGR) Given Average Recommendation of "Moderate Buy" by Analysts

UP Fintech Holding Limited (NASDAQ:TIGR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>The company’s Q3 revenue significantly beat analysts’ expectations of around $133 million.</li><li>TIGR’s total client assets hit a new peak of $61 billion, up almost 50% from last year.</li><li>The company added 31,500 new funded accounts during the quarter.</li></ul>&nbsp;Shares of UP Fintech Holding (TIGR) shot up 9% in premarket trading on Thursday&nbsp;after it reported a record-breaking third quarter print.<a href="https://stocktwits.com/symbol/TIGR">TIGR</a> was among the top-trending tickers on Stocktwits&nbsp;in the premarket session.<h2 class="st-heading-2">Q3 Results Shine</h2>UP Fintech posted a 73.3% year-on-year growth in Q3 revenue to a record $175.2 million, significantly beating analysts’ estimates of $132.8 million, according to Stocktwits data. On a sequential basis, revenue increased 26.3%.The company reported a record non-GAAP net income of $57 million, a nearly threefold increase from the prior-year period. Total client assets hit a new peak of $61 billion, up almost 50% from last year.Client growth accelerated, with 31,500 new funded accounts added during the quarter. This brought the total funded clients to 1.22 million, an 18.5% increase from a year ago. Trading activity remained healthy, with total quarterly volume growing 28.5% to $209.4 billion.“In Q3, market conditions continued to improve, and the Company once again achieved record-high revenue, profit and client assets. To date, we have already met our full-year target of adding 150,000 newly funded clients,” said UP Fintech's founder and CEO, Wu Tianhua.“This quarter, the average net asset inflows per newly funded client in Singapore and Hong Kong reached $62,000 and $30,000, respectively, while client assets in these two markets grew approximately 20% and 60% QoQ, highlighting a steady improvement in overall user quality.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>The results created quite a buzz on Stocktwits. Retail sentiment on the platform flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:925/90;" src="https://news.stocktwits-cdn.com/TIGR_png_0193c755c6.webp" alt="TIGR.png" width="925" height="90"><figcaption>TIGR's Sentiment Meter and Message Volumes at premarket on Dec. 4, 2025 | Source: Stocktwits</figcaption></figure>One user stated that the stock is undervalued.<stembedurl>https://stocktwits.com/qzz5013/message/638126374</stembedurl>Another user expects the stock to climb up to $15. It is currently at $9.4.<stembedurl>https://stocktwits.com/Polletjuh123/message/638127653</stembedurl>Year-to-date, TIGR stock has gained more than 35%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/meta-faces-fresh-eu-scrutiny-regulators-reportedly-consider-interim-restrictions-on-ai-rollout/cLILDdIRESS">Meta Faces Fresh EU Scrutiny: Regulators Reportedly Consider Interim Restrictions On AI Rollout</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Here’s Why TIGR Stock Rose In Premarket Today – And Retail Traders Think The Rally’s Just Starting

UP Fintech posted a 73.3% growth in Q3 revenue to a record $175.2 million, while net income jumped nearly threefold to a record $57 million.

Equity

UP Fintech: Quarterly Revenue and Profit Hit Record High; Global Client Assets Reach US$61 Billion

UP Fintech: Quarterly Revenue and Profit Hit Record High; Global Client Assets Reach US$61 Billion UP Fintech: Quarterly Revenue and Profit Hit Record High; Global Client Assets Reach US$61 Billion...

UP Fintech (NASDAQ:TIGR) Stock Price Down 7.9% - Should You Sell?

UP Fintech (NASDAQ:TIGR) Trading Down 7.9% - Here's What Happened...

Envestnet Asset Management Inc. Raises Position in UP Fintech Holding Limited $TIGR

Envestnet Asset Management Inc. increased its stake in shares of UP Fintech Holding Limited (NASDAQ:TIGR - Free Report) by 21.2% during the 2nd quarter, according to the company in its most recent...

TIGR or EVR: Which Is the Better Value Stock Right Now?

TIGR vs. EVR: Which Stock Is the Better Value Option?

Should You Buy, Sell or Hold FUTU Stock After 123% YTD Surge?

Futu Holdings' rapid client growth, global reach and profit strength fuel optimism, even as rate and rivalry pressures test its momentum.

TIGR vs. JPM: Which Stock Is the Better Value Option?

Zacks.com featured highlights include Phibro Animal Health, Daktronics, UP Fintech and Gold  Fields

Phibro, Daktronics, UP Fintech, and Gold Fields make Zacks' list of PEG-based value stocks positioned for market-beating returns.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

TIGR
UP Fintech Holding Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TIGR News

TIGRUP Fintech Holding Ltd - ADR